AR072265A1 - Compuesto de tiazolilo y oxazolilo isoquinolinonas y composicion farma-ceutica que lo comprende - Google Patents

Compuesto de tiazolilo y oxazolilo isoquinolinonas y composicion farma-ceutica que lo comprende

Info

Publication number
AR072265A1
AR072265A1 ARP090102266A ARP090102266A AR072265A1 AR 072265 A1 AR072265 A1 AR 072265A1 AR P090102266 A ARP090102266 A AR P090102266A AR P090102266 A ARP090102266 A AR P090102266A AR 072265 A1 AR072265 A1 AR 072265A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkenyl
independently selected
cycloalkyl
groups
Prior art date
Application number
ARP090102266A
Other languages
English (en)
Spanish (es)
Inventor
Roberto Pellicciari
Flavio Moroni
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR072265A1 publication Critical patent/AR072265A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP090102266A 2008-06-19 2009-06-19 Compuesto de tiazolilo y oxazolilo isoquinolinonas y composicion farma-ceutica que lo comprende AR072265A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7385708P 2008-06-19 2008-06-19

Publications (1)

Publication Number Publication Date
AR072265A1 true AR072265A1 (es) 2010-08-18

Family

ID=41087350

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102266A AR072265A1 (es) 2008-06-19 2009-06-19 Compuesto de tiazolilo y oxazolilo isoquinolinonas y composicion farma-ceutica que lo comprende

Country Status (12)

Country Link
US (3) US8299090B2 (enExample)
EP (2) EP2303895B1 (enExample)
JP (2) JP5564495B2 (enExample)
AR (1) AR072265A1 (enExample)
AU (1) AU2009260060B2 (enExample)
CA (1) CA2728454C (enExample)
DK (1) DK2303895T3 (enExample)
ES (1) ES2530815T3 (enExample)
HK (1) HK1212698A1 (enExample)
SA (1) SA109300394B1 (enExample)
TW (1) TWI471329B (enExample)
WO (1) WO2009155402A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA109300394B1 (ar) * 2008-06-19 2013-01-22 ويث ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها
WO2009155413A1 (en) * 2008-06-19 2009-12-23 Wyeth Thienyl- and furanyl-isoquinolinones and methods for using them
US9173395B2 (en) 2011-07-04 2015-11-03 Bayer Intellectual Property Gmbh Use of substituted isoquinolinones, isoquinolindiones, isoquinolintriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants
RU2606635C2 (ru) * 2011-07-13 2017-01-10 Сантен Фармасьютикал Ко., Лтд. Новое соединение, проявляющее ингибиторную активность в отношении parp
EP3325623B3 (en) 2015-07-23 2021-01-20 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
KR20200130856A (ko) 2018-03-13 2020-11-20 옹쎄오 암 치료에서 획득한 내성에 대한 디베이트 분자
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0005745B1 (en) * 1978-05-26 1982-07-14 Gruppo Lepetit S.P.A. Pyrazolo (3,4-c) and thiazolo (5,4-c) isoquinolines, methods for preparing them, these compounds for use as antiinflammatory, cns-depressant and anti-anxiety agents and pharmaceutical compositions thereof
ITMI20002358A1 (it) * 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
US7501412B2 (en) 2002-11-22 2009-03-10 Mitsubishi Tanabe Pharma Corporation Isoquinoline compounds and medicinal use thereof
ATE533812T1 (de) 2005-08-01 2011-12-15 Wietek Holding Gmbh Verfahren zur rezyklierung von kunststoff
WO2007149907A2 (en) 2006-06-20 2007-12-27 Abbott Laboratories Pyrazoloquinazolinones as parp inhibitors
SA109300394B1 (ar) * 2008-06-19 2013-01-22 ويث ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها
WO2009155413A1 (en) * 2008-06-19 2009-12-23 Wyeth Thienyl- and furanyl-isoquinolinones and methods for using them

Also Published As

Publication number Publication date
TWI471329B (zh) 2015-02-01
JP2011525185A (ja) 2011-09-15
WO2009155402A1 (en) 2009-12-23
JP5564495B2 (ja) 2014-07-30
TW201002725A (en) 2010-01-16
US8299090B2 (en) 2012-10-30
HK1156310A1 (en) 2012-06-08
JP2014122242A (ja) 2014-07-03
US20130059843A1 (en) 2013-03-07
US20150133443A1 (en) 2015-05-14
AU2009260060A1 (en) 2009-12-23
EP2896626A1 (en) 2015-07-22
CA2728454C (en) 2017-01-17
HK1212698A1 (en) 2016-06-17
EP2303895B1 (en) 2014-09-24
CA2728454A1 (en) 2009-12-23
US20090318442A1 (en) 2009-12-24
AU2009260060B2 (en) 2015-01-22
DK2303895T3 (en) 2015-01-12
US9265769B2 (en) 2016-02-23
SA109300394B1 (ar) 2013-01-22
EP2303895A1 (en) 2011-04-06
ES2530815T3 (es) 2015-03-05
US8906935B2 (en) 2014-12-09

Similar Documents

Publication Publication Date Title
AR072265A1 (es) Compuesto de tiazolilo y oxazolilo isoquinolinonas y composicion farma-ceutica que lo comprende
GT200500368A (es) Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios
AR068051A1 (es) Compuestos moduladores de la pi3k quinasa,composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del cancer.
AR074775A1 (es) Compuestos aminopiridina y carboxipiridina como inhibidores de fosfodiesterasa 10
PE20191540A1 (es) DERIVADOS DE PIRROLO [1,2-b] PIRIDAZINA
CL2007001731A1 (es) Compuestos derivados de imidazo[1,5-a]pirimidina; composicion farmaceutica; y uso para tratar o prevenir un trastorno asociado con el deterioro cognitivo, la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
CO6410305A2 (es) Inhibidores de poli (adp-ribosa) polimerasa (parp)
CL2007001732A1 (es) Compuestos derivados de imidazo[1,5-a]pirimidina; composicion farmaceutica; y uso para tratar o prevenir un trastorno asociado con el deterioro cognitivo, la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
CL2008001374A1 (es) Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia.
PE20141938A1 (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
AR101177A1 (es) Inhibidores de la syk
CY1117427T1 (el) Παραγωγο πυραζολοκινολινης ως αναστολεις pde9
AR074966A1 (es) Compuestos amino-heterociclicos
AR064010A1 (es) Inhibidores de la actividad de la akt
AR049399A1 (es) Difenilimidazopirimidina e -imidazol aminas como inhibidores de b-secretasa y metodo de obtencion de los mismos
AR049647A1 (es) Cis-imidazolinas
PE20121815A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
PE20121556A1 (es) 3,6-diazabiciclo[3.1.1]heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina
CL2011002838A1 (es) Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostéricos de receptores mglur2; composición farmacéutica; proceso para prepararla; y su uso en el tratamiento o la prevención de un trastorno del sistema nervioso central seleccionado de ansiedad y esquizofrenia, entre otros.
PE20201165A1 (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CR20170097A (es) Compuestos terapéuticamente activos y sus métodos de uso (divisional)
PE20130395A1 (es) Pirazolo[1,5-a]pirimidinas para tratamiento antiviral
CR20140085A (es) Inhibidores de pde10 de pirimidina

Legal Events

Date Code Title Description
FG Grant, registration